Pharmaceutical Executive-11-01-2015

The advantages for brand teams in leveraging independent agencies in their campaigns.

Building on our annual look at the industry's product pipeline, four key themes stand out that are driving the fast-changing environment for drug development.

Rare disease supporters deliver inspiration and optimism-as well as promise of regulatory cooperation.

The key steps to implementing the "patient access" model of the future

November 11, 2015.

In Pharm Exec’s 2013 end-of-year supply chain roundup, we began with a three-word vision of the immediate future that left little room for ambiguity: “Serialization is coming.” With the impending laws regarding “track and trace” promising to alter the way pharmaceuticals are packaged and shipped, we outlined how global pharma was gearing up to deal with the effects of serialization, and how companies needed to review their own internal practices and those of their outsourcing partners, as the need for technology solutions for both sides of the outsourc

The best approach to getting global brand campaigns to work all over the world

In the past few years, we’ve seen the biopharmaceutical industry begin to shift from a one-size-fits-all blockbuster approach toward an individualized, precision science model. This transformation has propelled companion diagnostics (CDx) into playing a more critical role than ever in the commercialization of biopharmaceutical therapeutics.

Doctors, advocates, politicians, feds jump on price-gouging bandwagon

Having reached the end of a decade of marked transformation and overhaul to Turkey’s healthcare system, identifying and acting on the resulting trends, dynamics, and initiatives will be key for the Turkish pharma industry going forward.